Biliary Tract Cancer Btc clinical trials

Explore recruiting biliary tract cancer btc clinical trials.

Recruiting biliary tract cancer btc studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Biliary Tract Cancer Btc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Germany, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of-care therapy alone for advanced HER2 positive biliary tract cancer

Germany, Belgium, Spain, Finland, Czechia, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors

Spain, Finland, France, Italy, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Biliary Tract Cancer Btc trials by city

Biliary Tract Cancer Btc clinical trials

Recruiting biliary tract cancer btc studies right now

Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Cosiporfin Sodium for Injection Photodynamic Therapy

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

Also recruiting in Europe

SEVILLA_A randomised, phase II trial to evaluate the efficacy of ivonescimab, a PD 1/VEGF bispecific antibody, versus FOLFOX as second line therapy for locally advanced or metastatic biliary tract cancers

IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of-care therapy alone for advanced HER2 positive biliary tract cancer

EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Phase 1/2 Open-label Study of BMS-986466 in Combination with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Advanced Solid Tumors

Biliary Tract Cancer Btc trials by city

Other conditions